UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1130-13
Program Prior Authorization/Notification
Medication Hetlioz®, Hetlioz LQ™ (tasimelteon)
P&T Approval Date 5/2014, 5/2015, 5/2016, 5/2017, 5/2018, 5/2019, 5/2020, 5/2021, 11/2021,
2/2022, 2/2023, 1/2024, 3/2025
Effective Date 6/1/2025
1. Background:
Hetlioz is a melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake
Disorder in adults and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in
patients 16 years of age and older. Hetlioz LQ is an oral suspension and is indicated for the
treatment of nighttime sleep disturbances in SMS in pediatric patients 3 years to 15 years of age.
Non-24-hour sleep wake disorder is also called Free-Running Disorder, Circadian Rhythm Sleep
Disorder – Free Running (or Non-Entrained) Type, and Hypernychthemeral Syndrome.
2. Coverage Criteriaa:
A. Hetlioz or Hetlioz LQ will be approved based on one of the following criteria:
1. Diagnosis of non-24-hour sleep wake disorder
-OR-
2. Diagnosis of nighttime sleep disturbances in Smith-Magenis-Syndrome (SMS)
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits and/or Medical Necessity may be in place.
© 2025 UnitedHealthcare Services, Inc.
1
4. References:
1. Hetlioz [package insert]. Washington, D.C.: Vanda Pharmaceuticals Inc.; February 2021.
2. International Classification of Sleep Disorders: Diagnostic & Coding Manual. 3rd ed.
Westchester, IL: American Academy of Sleep Medicine; 2014.
3. Auger RR, Burgess HJ, Emens JS, et al. Clinical Practice Guidelines for the Treatment of
Intrinsic Circadian Rhythm Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wak
Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD) J Clin Sleep
Med 2015;11(10):1199 –1236.
Program Prior Authorization/Notification – Hetlioz, Hetlioz LQ (tasimelteon)
Change Control
5/2014 New program.
5/2015 Annual review. No changes.
5/2016 Annual review. No changes to clinical intent. Updated background and
references.
5/2017 Annual review with no changes to coverage criteria. Updated references.
5/2018 Annual review. No changes.
5/2019 Annual review. No changes.
5/2020 Annual review. Updated references.
5/2021 Updated to allow coverage of nighttime sleep disturbances in Smith-
Magenis Syndrome based on updated labeling with newly approved
indication. Added Hetlioz LQ to criteria.
11/2021 Removed requirement that patient is totally blind.
2/2022 Administrative changes.
2/2023 Annual review. Added state mandate language. Updated references.
1/2024 Annual review. Updated references.
3/2025 Increased authorization to 12 months.
© 2025 UnitedHealthcare Services, Inc.
2